Peptide record

TPDB92421

R-DIM-P-LF11-334 Antibacterial Anticancer Toxicity modified_plain modified
16 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB92421
R-DIM-P-LF11-334
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia CancerPPD 2.0
modified_plain
Yes
A 16-aa modified multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from Peptipedia and CancerPPD 2.0, with an available 3D structural model.
C-terminal: Amidation
Sequence
PWRIRIRRPRRIRIWP-NH2
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
16 reviewed residue count
Amidation Activity
L Activity
Linear Activity
Free Activity
Anticancer Activity
Synthetic Activity
Evidence Records 3 records
Evidence 1 Activity

Activity

LC50
LC50 = 6.6 ± 0.3 µM
Anticancer
6.6

Target

Skin Cancer
A-375
Skin

Assay & Model

MTS assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
EP_2943215_B1

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

LC50
LC50 = 3.4 ± 0.4 µM
Anticancer
3.4

Target

Skin Cancer
SBcl2
Skin

Assay & Model

MTS assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
EP_2943215_B1
Evidence 3 Activity

Activity

LC50
LC50 = 5.0 ± 0.1 µM
Anticancer
5.0

Target

Skin Cancer
WM164
Skin

Assay & Model

MTS assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
EP_2943215_B1